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The mild neuroinflammation hypothesis of schizophrenia was introduced by Bechter 
in 2001. It has been hypothesized that a hypofunction of glutamatergic signaling via 
N-methyl-D-aspartate receptors (NMDARs) and hyperactivation of dopamine D2 
receptors play a role in schizophrenia. The triplet puzzle theory states that sets of triplet 
amino acid homologies guide two different receptors toward each other and contrib-
utes to the formation of a receptor heteromer. It is, therefore, proposed that putative 
NMDAR-C-C chemokine receptor type 2 (CCR2), NMDAR-C-X-C chemokine receptor 
type 4 (CXCR4), and NMDAR- interleukin 1 receptor type II (IL1R2) heteromers can be 
formed in the neuronal networks in mild neuroinflammation due to demonstration of 
Gly-Leu-Leu (GLL), Val-Ser-Thr (VST), and/or Ser-Val-Ser (SVS) amino acid homologies 
between these receptor protomers. This molecular process may underlie the ability to 
produce symptoms of schizophrenia in mild neuroinflammation. In this state, volume 
transmission (VT) is increased involving increased extracellular vesicle-mediated VT from 
microglia and astroglia. These vesicles may contain CCR2, CXCR4, and/or IL1R2 as 
well as their ligands and upon internalization by endocytic pathways into neurons can 
form heteroreceptor complexes with NMDAR in the plasma membrane with pathological 
allosteric receptor–receptor interactions involving increased internalization and reduced 
NMDAR signaling. The triplet puzzle theory also suggests the formation of putative D2R-
CCR2, D2R-CXCR4, and D2R-IL1R2 heteromers in mild neuroinflammation in view of 
their demonstrated sets of Leu-Tyr-Ser (LYS), Leu-Pro-Phe (LPF), and/or Ser-Leu-Ala 
(SLA) triplet homologies. These D2R heteroreceptor complexes may also contribute to 
schizophrenia-like symptoms in mild neuroinflammation by enhancing D2R protomer 
function.
Keywords: receptor–receptor interactions, schizophrenia, neuroinflamation, NMDAr, chemokine receptors, 
cytokine receptors, heteroreceptor complexes, volume transmission
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iNtrODUctiON
The mild neuroinflammation hypothesis of schizophrenia was 
introduced by Bechter (1–3). Recent work supports a role of 
inflammation in schizophrenia (4) and a relevant cellular basis 
appears to be microglia, which upon activation release proinflam-
matory cytokines (4, 5). It is still unclear, however, if the classical 
antibiotic drug minocycline can be used as an antipsychotic drug 
in spite of its ability to block microglia activation. It is known 
that microglia plays an important role in brain development and 
possesses protective and destructive functions in neuroinflam-
mation (6–8).
CSF studies may be especially informative on brain events, at 
least in the clinical situation, and can be performed repeatedly 
even during acute psychotic episodes. Such studies demon-
strated, both in affective and schizophrenic spectrum disorders, 
the prevalence of activated CSF cells similar to the situation in 
neurological neuroinflammatory disorders (9, 10). In addition, at 
least three immunological subgroups were found in affective and 
schizophrenic spectrum disorders as defined by established CSF 
examination (11) and a subgroup with increased CSF neopterin 
(12). In another study, all patients investigated demonstrated an 
increase of IL8 (13). Taken together, between 70 and 100% of 
severely diseased patients with the affective and schizophrenic 
spectrum disorder presented certain CSF abnormalities (14, 
15). These findings supported the mild encephalitis (ME) 
hypothesis of these disorders (1, 2, 16). Further support came 
from the neurological field with the first description of NMDAR 
autoimmune encephalitis (17, 18). The more general relevance 
of the ME hypothesis is suggested by epidemiological findings 
demonstrating that infections and autoimmune disorders are 
important risk factors in schizophrenia bipolar and depressive 
disorders (19–21). Furthermore, recent CSF studies in larger 
groups of similar psychiatric patient groups also supported this 
view (22–24).
There is an agreement that the N-methyl-d-aspartate recep-
tor (NMDAR) hypofunction plays an important role in the 
schizophrenia disease development (25). Previously it was found 
that chronic brain inflammation can produce a decline in both 
hippocampal GluN1 NMDARs and GluN2A and GluN2B subu-
nits of NMDARs which likely is mainly caused by reductions in 
their transcriptional mechanisms (26, 27). They may be linked to 
cognitive deficits is schizophrenia.
It is, therefore, of high interest that schizophrenia-like symp-
toms can often be found in patients with NMDAR antibody 
induced encephalitis (17, 19, 28–30). The NMDAR autoantibod-
ies have been shown to lead to specific, titer-dependent, reversible 
loss of NMDARs, the dysbalance within the network function 
being able to explain a spectrum of symptoms (31). It seems pos-
sible that the mechanism can involve disturbances in NMDAR 
function through interactions with the NMDAR antibody leading 
inter alia to NMDA receptor internalization and breakdown (31). 
On the other hand, a broad repertoire of antibody-secreting cells 
is enriched in the CNS during encephalitis producing different 
types of autoantibodies in parallel in the CSF (32). In addition, 
for neuronal damage in autoimmune encephalitis cytotoxic, 
T cells may be responsible not the autoantibodies. Triggers of 
autoimmune encephalitis may be cancers or virus infections or 
remain unknown (33). So far, the situation is rather similar to 
that predicted with the ME hypothesis. The latter is further sup-
ported by CSF findings (14, 15) and not least by rare cases of acute 
psychosis with brain biopsy showing definite but mild neuroin-
flammation in the cerebral cortex (34–36). Recent evidence for 
a more general relevance of the ME hypothesis comes also from 
a postmortem study showing an increased number of immune 
cells in the brain seemingly linked to a minor blood brain barrier 
breakdown (37).
Apparently, in classical and ME, one can plausibly expect 
some general pathological mechanisms but potentially also spe-
cific pathological mechanisms to be involved in parallel. There 
exists no clearcut evidence that specific autoimmunity explains 
the whole disorder in autoimmune encephalitis (38) nor that it 
represents an exclusive single pathological mechanism. In mul-
tiple sclerosis (MS), there is an early involvement of the cerebral 
cortex found in both experimental allergic encephalomyelitis 
(39) and in human MS (40). The interesting findings by Najjar 
et  al. (34–36) in cortical biopsies may similarly represent not 
only proof for mild local neuroinflammation but may in addition 
indicate a more distributed mild neuroinflammatory process, the 
latter indicated by the findings of Bogerts et al. (37).
The current perspective article will discuss the different 
molecular mechanisms that may underlie the ability of neuro-
inflammation to produce positive, negative, and/or cognitive 
symptoms of schizophrenia. It likely involves the release of 
chemokines and cytokines from activated microglia, astroglia, 
and monocytes (41, 42), which via volume transmission (VT) can 
target their receptors on glia and neurons (43, 44). There may also 
exist an increased extracellular vesicle-mediated VT (44) from 
glia and megacaryocytes. Glial and immune cells may contain 
receptor proteins and different forms of mRNAs for chemokine 
and cytokine receptors in mild neuroinflammation. Extracellular 
vesicles containing mRNA and proteins for these receptors 
can via VT communication have a relevant role for producing 
schizophrenia-like symptoms by being internalized via e.g., cell 
adhesion receptors into the neuronal component of glia–neuron 
networks. Extracellular vesicles containing e.g., the cytokine and 
chemokine receptors may be taken up by an uptake mechanism 
that depends on proteins located both on the neuronal target cell 
at extrasynaptic and/or synaptic sites and on the extracellular 
vesicle (45). The extracellular vesicles are then internalized by a 
number of endocytic pathways. In this process, the internalized 
receptors can reach e.g., early endosomes and be rapidly returned 
to the plasma membrane (46) where they are proposed to interact 
with extrasynaptic and synaptic NMDARs and D2Rs, indicated 
to be involved in schizophrenia. This may lead to pathological 
receptor–receptor interactions in neurons in brain areas with 
mild neuroinflammation (43, 44).
The allosteric receptor–receptor interactions in D2R hetero-
complexes are already indicated to play a role in schizophrenia, 
especially the antagonistic A2AR–D2R interactions in A2AR–
D2R heterocomplexes (47–49). Using the triplet puzzle theory 
(50), four sets of triplet amino acid homologies were found 
between the A2AR and D2R protomers which may contribute 
to the formation of the A2AR–D2R heterocomplexes and to the 
tABLe 1 | example of schizo triplets in the interface of human receptor heteromers.
receptor heteromer reference ser-val-ser 
(svs)
Gly-Leu-Leu 
(GLL)
val-ser-thr 
(vst)
Leu-tyr-ser 
(LYs)
Leu-Pro-
Phe (LPF)
ser-Leu-Ala 
(sLA)
GABAB1–GABAB2 (54–56) − # − − − −
GABAB1–CXCR4 (57) # − # − − −
NMDA–CCR2 Possible heteromer − # − + − −
NMDA-interleukin 1 receptor type II (IL1R2) Possible heteromer # − − − − −
NMDA–CXCR4 Possible heteromer + − # + − −
MOP–DOP (58) − − − # # −
CCR2–CXCR4 (59) − − − # − −
DOP–CXCR4 (60) − − − # # −
5HT1A–5HT1B (61) − − − − # #
5HT1A–5HT7 (62) − − − − # #
ADRA2A–ADRA2B (63) − − − − − #
ADRB2–ADRB3 (64) − − − − # #
D2–CCR2 Possible heteromer − − − # − −
D2–IL1R2 Possible heteromer − − − − # #
D2–CXCR4 Possible heteromer − − − # # −
#, yes in both receptors and may mediate their interaction; +, yes in both receptors; −, no in any receptor.
Location: ec, extracellular; ic, intracellular; TM, transmembrane; SVS—ic GABAB1 # CXCR4; ec NR2A,B,D # IL1R2(N-terminal); GLL—TM GABAB1 # GABAB2; ic NR2A # CCR2(C-
tail); VST—ic GABAB1 # CXCR4 (C-tail), NR2A # CXCR4(C-tail), NR1-1,4,5(C-tail) # CXCR4(C-tail); LYS—TM MOP, DOP, CXCR4, D2; LPF—TM MOP, DOP, 5HT1A,B, 5HT7; TM 
CXCR4 # D2(TM’ec); ec IL1R2 # D2(TM’ec); SLA—TM 5HT1A,B, 5HT7, ADRA2A,B, ADRB2,3; TM IL1R2 # D2. The highlighted text in red color represent the new postulated 
heteroreceptor complexes based on the Triplet Puzzle Theory
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development of the antagonistic A2A–D2 receptor–receptor 
interactions (47–49).
POssiBLe MOLecULAr MecHANisMs 
BAseD ON tHe triPLet PUZZLe 
tHeOrY cONtriBUtiNG tO 
scHiZOPHreNiA-LiKe sYMPtOMs iN 
MiLD NeUrOiNFLAMMAtiON
triplet Puzzle theory supports the 
Formation of Glutamate NMDAr–
cytokiner/chemokiner Heteroreceptor 
complexes through Gly-Leu-Leu (GLL), 
val-ser-thr (vst), and ser-val-ser (svs) 
Homologies
In 2010, based on a bioinformatic approach, it was possible to 
indicate that receptor that form heterodimers show triplet amino 
acid homologies (50). This was not observed in pairs of receptors 
that do not form heterodimers. It was, therefore, proposed that 
these triplet homologies participate in the receptor interface and 
gives a code that facilitates the formation of the heterodimer. It 
was named the triplet puzzle theory (50, 51). The code formed 
from the triplet amino acid homologies may assist in guiding the 
receptors toward each other.
Such protriplet homologies appear to be phylogenetically old 
mechanisms for protein recognition and are already found in 
integrins (an alpha–beta heterodimer) of marine sponges (52) 
and remain in human D2 receptor heteromers (53).
It is of particular interest that the NMDAR shows one protri-
plet amino acid homology with CCR2 (GLL), C-X-C chemokine 
receptor type 4 (CXCR4) (VST), and interleukin 1 receptor type 
II (IL1R2) (SVS) (Table 1) as previously observed (43). The GLL 
protriplet of CCR2 is located in the C-tail and may interact with 
the GLL of the intracellular part of NR2A (Table 1). The VST pro-
triplet of CXCR4 is also found in the C-tail and may interact with 
the VST protriplet of the intracellular part of NR2A (Table 1). 
The VST protriplet of CXCR4 may also interact with the VST in 
the NR1-1,4,5 subunits present in the C-tail (Table 1). The SVS 
protriplet is located in the N-terminal of IL1R2 and may interact 
with the SVS protriplet in the extracellular part of NR2A,B,D 
(Table 1).
Interleukin 1 receptor type II is a decoy receptor that can 
bind to IL1α, IL1β, and IL1R antagonist. It can also interact with 
IL1R accessory protein. It should be noticed that the ITGA-ITGB 
heterodimer shows a SVS protriplet homology and the GABA 
B receptor (GABAB1-GABAB2 heterodimer) a GLL protriplet 
homology and the known GABAB1-CXCR4 heterodimer inter 
alia a VST and a SVS homology (Table 1). These observations 
further support the current view that NMDARs can form heter-
ormers with CCR2, CXCR4, and IL1R2.
In mild neuroinflammation, it is proposed that VT is 
increased involving increased extracellular vesicle-mediated VT 
from microglia and astroglia (see above). It should, therefore, be 
considered that these vesicles may contain CCR2, CXCR4, and/
or IL1R2, which upon internalization into neurons can form 
heteroreceptor complexes with NMDAR with pathological allos-
teric receptor–receptor interactions (Figure 1). If these receptor 
mechanisms lead to a hypofunction of the NMDAR protomer, 
they represent one mechanism for the schizophrenia-like effects 
seen in mild neuroinflammation (3). If the mild neuroinflamma-
tion takes place in the hippocampus and the cerebral cortex, the 
pyramidal nerve cells, key nerve cells in the cortical, and hip-
pocampal circuits will also be affected in view of their expression 
of NMDA receptors. It will lead to deficits in cognitive functions 
and contribute to negative symptoms of schizophrenia.
FiGUre 1 | illustration of the potential chemokine and cytokine receptor transfer via extracellular vesicle-volume transmission (vt) from immune 
and microglial cells to striatopallidal GABA neurons [containing dopamine (DA) D2rs and NMDArs] and hippocampus pyramidal neurons 
(containing NMDA receptors) in mild inflammation. One mechanism is shown for how chemokine C-X-C chemokine receptor type 4 (CXCR4) and cytokine 
receptor IL1-R2 including their mRNAs can produce schizophrenia-like symptoms in neuroinflammation. These receptors may be transferred via extracellular 
vesicle-mediated VT from immune cells, activated microglia, and/or astroglia to nerve cells containing DA D2R and NMDA receptors. Upon internalization, the 
receptors CXCR4 and IL1-R2 can according to the triplet puzzle theory (see table 1) form complexes with DA D2R and NMDAR as illustrated here. (A) is shown the 
D2R-interleukin 1 receptor type II (IL1R2) heteromers in striatopallidal GABA neurons and how they reach the plasma membrane NMDAR via early endosomes and 
recycling endosomes. (B) is shown the NMDAR-CXCR4 heteromers in the pyramidal nerve cells in the hippocampus with microglial extracellular vesicles containing 
CXCR4 and also SDF-1alpha reaching the NMDAR in the plasma membrane via internalization and endosomes in the pyramidal cells. Through the development of 
novel allosteric receptor–receptor interactions in such heteroreceptor complexes, D2R and NMDAR signaling may become pathologically altered contributing to 
schizophrenia-like symptoms.
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These disturbances may become enhanced by an increase 
in the glia release of the endogenous cytokine and chemokine 
ligands for these receptors. The agonist induced receptor– 
receptor  interactions can amplify the reduction of NMDAR 
function in these heterocomplexes and thus help develop the 
schizophrenia episodes. It will be of high interest to test if the 
putative NMDAR-CCR2, NMDAR-CXCR4, and NMDAR-IL1R2 
heteroreceptor complexes in fact exist using the in situ proxim-
ity ligation assay in brain tissue. It is postulated that a reduced 
NMDAR signaling develop in these heteroreceptor complexes 
through the agonist activated chemokine and cytokine receptor 
protomers reducing the NMDAR signaling via allosteric mecha-
nisms in these heterocomplexes. This may also lead to increases 
in the internalization of these heterocomplexes to late endosomes 
and lysosomes with a reduction in the density of NMDA recep-
tors. It is unknown if the cytokine and/or chemokine-activated 
receptor protomer involves a negative allosteric modulation of 
the glutamate-binding site on GluN2 and/or a negative allosteric 
modulation of the glycine modulatory site on GluN1 (25).
C-C chemokine receptor type 2 with its ligand CCL2 plays a 
major role in immunobiology and neurobiology (65). It is mainly 
located on monocytes and is involved in systemic and brain 
inflammation. CXCR4 and its ligands CXCL12 are involved in 
the pathogenesis of brain disease and participate in neuron–glial 
interactions and in neurotoxicity (66, 67). The IL1R2 exists both 
in soluble and membrane bound forms, shows no transmembrane 
signaling, and is regarded as a decoy receptor for IL1 signaling 
However, it can also act as a binding protein in the membrane and 
interact with the IL1R accessory protein (68). This accessory pro-
tein also exists as an alternatively spliced brain-specific isoform 
having a significant role in homeostatic sleep (69).
According to the triplet puzzle hypothesis, it can bind to the 
NMDAR [Table 1; see also Ref. (51)] and form a NMDAR–IL1R2 
complex in which NMDAR function is postulated to become 
reduced. Previous work (70) indicated that this receptor can 
participate in Alzheimer’s disease, but its biological function is 
unknown. It may participate in anti-inflammation and help keep 
the neuroinflammation at a low level.
5Borroto-Escuela et al. Dysfunctional Heteroreceptor Complexes and Neuroinflamation
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triplet Puzzle theory supports the 
Formation of Dopamine (DA) D2r–cytokine 
receptor/chemokine receptor 
Heteroreceptor complexes through LYs, 
LPF, and sLA triplet Homologies
There exists dysregulation of the DA neurons in the pathophysiol-
ogy of schizophrenia (71). The therapeutic effects of typical and 
atypical antipsychotic drugs are mainly mediated via blockade 
of the DA D2 receptors (72, 73) located postjunctionally in the 
mesolimbic-cortical DA neurons (74–76). The D2Rs are mainly 
located outside the DA synapses and targeted by extracellular DA 
VT (76). Over the last decades, the discovery was made that D2Rs 
participate in many different types heteroreceptor complexes in 
which D2R protomers directly interact via allosteric mechanisms 
with other receptor protomers to integrate biological signals 
changing D2R signaling (47, 49). Some of them offer new targets 
for the therapeutic effects of D2R antagonists. In other D2R 
heteroreceptor complexes, the blockade of the D2R protomers by 
antipsychotic drugs may instead produce side-effects.
It is of particular interest that the NR2B subunit of the 
NMDAR interacts with the D2R in the glutamate synapses (77), 
which leads to an antagonistic allosteric receptor–receptor inter-
action reducing NMDA signaling in the heteroreceptor complex. 
Thus, DA through VT may diffuse into the glutamate synapses, 
activate D2R protomers, and reduce NMDAR-mediated synaptic 
glutamate transmission, which should enhance schizophrenic 
symptoms according to current hypotheses. The D2Rs and their 
heteroreceptor complexes are mainly located in the ventral 
striatopallidal GABA anti-reward neurons. Their enhanced inhi-
bition by enhanced D2R signaling leading to reduced NMDAR 
signaling should markedly bring down anti-reward activity in 
this pathway, which can contribute to a malfunction of salience in 
schizophrenia with all stimuli becoming relevant and disturbing 
ongoing behavior (49).
It is, therefore, of high interest that, according to the triplet 
puzzle theory, D2Rs can form heteroreceptor complexes with 
CCR2, IL1R2, and CXCR4 as indicated for the first time in the 
current article (Table  1). Three “schizo triplets” were found: 
LYS, LPF, and SLA. The possible D2R-IL1R2 heterodimer had 
two sets of triplet homologies, LPF and SLA. LPF is located in 
the TM6/extracellular region of the D2R and in the extracellular 
region of the IL1R2 (Table 1). SLA is instead located in TM2 of 
the D2R and in the TM region of IL1R2 (Table 1). The possible 
D2R-CXCR4 heterodimer also shows two sets of triplet homolo-
gies, one is again LPF, this time located in the interface between 
TM6-TM2 with the LPF located in the TM2 (Table 1). The other 
triplet is LYS, which is located in the TM7 of the D2 and in TM3 
of the CXCR4 (Table 1) indicating that TM7 and TM3 of the D2R 
and CXCR4, respectively, can also participate in this interface. 
The possible D2R-CCR2 heterodimer only exhibits one set of 
triplet homology that may help mediate the interaction. Also, in 
this case, the LYS triplet is found and here present in the TM1 
of CCR2 that may interact with the LYS triplet in TM7 of D2R.
It is proposed that D2R-CCR2, D2R-IL1R2, and D2R-CXCR4 
heteromers can be formed upon mild neuroinflammation in the 
brain, especially in the ventral striatum. This may contribute to 
positive schizophrenic symptoms by enhancing D2R inhibitory 
function in critical brain circuits like the ventral striatopallidal 
GABA anti-reward pathway leading to exaggerated salience 
development (Figure 1). Both chemokine and cytokine receptors 
appear to be involved in forming complexes with the DA D2Rs 
as is the case with NMDARs. It should also be underlined that 
the NMDARs interact with the same chemokine and cytokine 
receptor subtypes as the D2Rs but using different sets of triplet 
amino acid homologies.
Other GPCR Heteroreceptor Complexes with LYS, 
LPF, and SLA Homologies
It is of interest that a number of 5HT1A isoreceptor complexes 
and α2- and β-adrenergic isoreceptor complexes (78) also pos-
sess sets of LYS, LPF, and SLA protriplets that may assist in the 
formation of these isoreceptor complexes (Table  1). Previous 
work demonstrated also crosstalk between opioid and chemokine 
receptor subtypes (79) and extensive formation of heteromers 
take place between opioid and receptor subtypes according to 
the triplet puzzle theory (80). In Table 1, we report some results 
from this study showing that LYS and LPF protriplets may also 
participate in opioid and chemokine isoreceptor complexes as 
well as in the delta opioid-CXCR4 heterodimer. Their possible 
role in schizophrenic symptoms in neuroinflammation remains 
to be explored, but they may have an impact on pain and reward 
mechanisms (80).
Hypothesis: Glial cytokine and chemokine 
receptor subtype transfer into Neurons in 
Mild Neuroinflammation can Produce 
Novel Dysfunctional NMDAr and D2r 
Heteroreceptor complexes contributing 
to schizophrenia Development
This hypothesis is based on the existence of not only soluble 
VT signals but also of extracellular vesicle-mediated VT signals 
(44). In 2006, it was found that exosomes can be released from 
cortical neurons in culture (81). In 2012, cell cultures were 
demonstrated to transfer GPCRs via extracellular vesicles to 
other cells and also form GPCR heteromers in the recipient 
cells by direct interactions with their GPCRs and A2AR-D2R 
heteromers developed (82). Glial cells, especially the microglia, 
are activated in inflammation and can release a number of 
chemokines and cytokines as soluble VT signals and produce 
a panorama of cytokine and chemokine receptors (6, 83). 
They may communicate as soluble VT signals (ligands) and 
via extracellular vesicle-mediated VT as to receptors and their 
receptor mRNAs (43, 44). The extracellular vesicles may then via 
cell adhesion receptors become internalized into neurons and 
their cargo released. In the neurons, CCR2, CXCR4, and IL1R2 
can according to the triplet puzzle theory (see above) interact 
with NMDARs, known to be disturbed in schizophrenia, and as 
discovered in the current paper with D2Rs, the major target for 
currently used antipsychotic drugs.
The hypothesis states that the NMDAR protomer develops 
a hypofunction in mild neuroinflammation due to antagonistic 
receptor–receptor interactions produced by activation of the 
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CCR2, CXCR4, and/or IL1R2 protomers in the plasma mem-
brane. Their agonist ligands are released by the microglia and/
or immune cells and/or astroglia into the extracellular fluid to 
activate these chemokine and cytokine receptor protomers in 
the plasma membrane. The current findings based on the triplet 
puzzle theory indicate that the CCR2, CXCR4, and/or IL1R2 can 
also interact with D2Rs through such mechanisms. Based on 
the antipsychotic actions of D2R antagonists, it is proposed that 
enhancing allosteric receptor–receptor interactions develop in 
the D2R-CCR2, D2R-CXCR4, and D2R-IL1R2 heteromers upon 
agonist activation of these chemokine and cytokine receptors 
leading to increases in D2R protomer signaling with development 
of schizophrenia-like symptoms.
It will be of high interest to test in cellular models if, in fact, 
the NMDAR and D2R heteroreceptor complexes with CCR2, 
CXCR4, and/or IL1R2 protomers are formed using the BRET 
methodology and the postulated allosteric receptor–receptor 
interactions develop. We will also test if these NMDAR and D2R 
heteroreceptor complexes exist in the ventral and dorsal striatum 
in models of neuroinflammation using the in  situ proximity 
ligation assay and if the proposed allosteric receptor–receptor 
interactions occur in these brain regions upon neuroinflamma-
tion with or without agonist ligands for the CCR2, CXCR4, and/
or IL1R2 protomers.
cONcLUDiNG reMArKs
It is proposed that the following mechanisms can contribute to 
schizophrenia-like symptoms in mild neuroinflammation:
• Extracellular vesicle-mediated VT with receptor and ligand 
transfer from glial networks to neuronal networks involving 
distinct cytokine and chemokine receptors and their agonist 
ligands can lead to formation of dysfunctional and separate 
NMDAR and D2R heteroreceptor complexes containing 
CCR2, CXCR4, and/or IL1R2 according to the triplet puzzle 
theory. The agonist ligands for these three receptors may 
produce allosteric receptor–receptor interactions in these 
dysfunctional complexes reducing NMDAR and increasing 
D2R signaling in the plasma membrane. Schizophrenia-like 
symptoms may, therefore, develop.
• However, there is no consensus as to which psychopathologi-
cal symptoms are specific for schizophrenia. There is in fact 
clear evidence that symptoms in any type of encephalitis are in 
principle non-specific and variant. As far as the mechanisms 
proposed in the current paper, they may, from a theoretical 
perspective, contribute not only to schizophrenia symptoms 
but may also participate in bipolar disorder and other affective 
disorders associated with mild neuroinflammation.
• The hypothesis introduced on the formation of distinct 
NMDAR–cytokine receptor/chemokine receptor and D2R–
cytokine receptor/chemokine receptor heterocomplexes with 
pathological receptor–receptor interactions in the brain upon 
mild neuroinflammation will primarily be tested as follows: 
the possible existence of the putative and distinct NMDAR 
and D2R heteroreceptor complexes will be studied in cellular 
models and brain models of neuroinflammation using prox-
imity ligation assay and BRET. Then, it will be tested in these 
models if their allosteric receptor–receptor interactions will 
lead to a reduction of NMDAR signaling and to increases in 
D2R signaling in the above heteroreceptor complexes. Finally, 
if positive results are obtained, the critical role of the demon-
strated sets of triplet amino acid homologies for the formation 
of these heteroreceptor complexes and their receptor–receptor 
interactions will be tested through mutations of these triplet 
homologies.
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